The Journal of Pediatrics
Volume 154, Issue 4 , Pages 514-520.e4 , April 2009

Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial Assessing the Efficacy and Safety of Proton Pump Inhibitor Lansoprazole in Infants with Symptoms of Gastroesophageal Reflux Disease

  • Susan R. Orenstein, MD

      Affiliations

    • From the University of Pittsburgh School of Medicine, Pittsburgh, PA
    • Corresponding Author InformationCorrespondence to: Susan R. Orenstein, MD, 303 Church Lane, Pittsburgh, PA 15238
    • ,
  • Eric Hassall, MBChB, FRCPC

      Affiliations

    • Division of Gastroenterology, BC Children's Hospital/University of British Columbia, Vancouver, BC, Canada
    • ,
  • Wanda Furmaga-Jablonska, MD, PhD

      Affiliations

    • Department of Neonate and Infant Pathology and Cardiology, Medical University of Lublin, Lublin, Poland
    • ,
  • Stuart Atkinson, MBChB

      Affiliations

    • Takeda Global Research & Development Center, Inc, Deerfield, IL
    • ,
  • Marsha Raanan, MS

      Affiliations

    • Takeda Global Research & Development Center, Inc, Deerfield, IL

Received 2 June 2008 ,Revised 28 July 2008 ,Accepted 30 September 2008.

References 

  1. Rudolph CD, Mazur LJ, Liptak GS, Baker RD, Boyle JT, Colletti RB, et al. Guidelines for evaluation and treatment of gastroesophageal reflux in infants and children: recommendations of the North American Society for Pediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr. 2001;32(Suppl 2):S1–S31
  2. Barron JJ, Tan H, Spalding J, Bakst AW, Singer J. Proton pump inhibitor utilization patterns in infants. J Pediatr Gastroenterol Nutr. 2007;45:421–427
  3. Orenstein SR, Hassall E. Infants and proton pump inhibitors: tribulations, no trials. J Pediatr Gastroenterol Nutr. 2007;45:395–398
  4. Khoshoo V, Edell D, Thompson A, Rubin M. Are we overprescribing antireflux medications for infants with regurgitation?. Pediatrics. 2007;120:946–949
  5. Li JS, Eisenstein EL, Grabowski HG, Reid ED, Mangum B, Schulman KA, et al. Economic return of clinical trials performed under the pediatric exclusivity program. JAMA. 2007;297:480–488
  6. Fossmark R, Johnsen G, Johanessen E, Waldum HL. Rebound acid hypersecretion after long-term inhibition of gastric acid secretion. Aliment Pharmacol Ther. 2005;21:149–154
  7. Orenstein SR, Shalaby TM, Devandry SN, Liacouras CA, Czinn SJ, Dice JE, et al. Famotidine for infant gastro-oesophageal reflux: a multi-centre, randomized, placebo-controlled, withdrawal trial. Aliment Pharmacol Ther. 2003;17:1097–1107
  8. Orenstein SR, Cohn JF, Shalaby TM, Kartan R. Reliability and validity of an infant gastroesophageal reflux questionnaire. Clin Pediatr. 1993;32:472–484
  9. Orenstein SR, Shalaby TM, Cohn JF. Reflux symptoms in 100 normal infants: diagnostic validity of the Infant Gastroesophageal Reflux Questionnaire. Clin Pediatr. 1996;35:607–614
  10. Shalaby TM, Orenstein SR. Efficacy of telephone teaching of conservative therapy for infants with symptomatic gastroesophageal reflux referred by pediatricians to pediatric gastroenterologists. J Pediatr. 2003;142:57–61
  11. Orenstein SR, McGowan JD. Efficacy of conservative therapy as taught in the primary care setting for symptoms suggesting infant gastroesophageal reflux: prospective validated assessment by the I-GERQ-R. J Pediatr. 2008;152:310–314
  12. Springer M, Atkinson S, North J, Raanan M. Effect of lansoprazole on safety, pH, and GERD-associated symptoms in pediatric subjects less than 1 year of age. Pediatr Drugs. 2008;10:255–263
  13. Zhang W, Kukulka M, Witt G, Sutkowski-Markmann D, North J, Atkinson S. Age-dependent pharmacokinetics of lansoprazole in neonates and infants. Pediatr Drugs. 2008;10:265–274
  14. Hassall E. Talk is cheap, often effective: symptoms in infants often respond to nonpharmacologic measures. J Pediatr. 2008;152:301–303
  15. Tran A, Rey E, Pons G, Pariente-Khayat A, D'Athis P, Sallerin V, et al. Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children. Clin Pharmacol Ther. 2002;71:359–367
  16. Tolia V, Bishop PR, Tsou VM, Gremse D, Soffer EF, Comer GM, et al. Multicenter, randomized, double-blind study comparing 10, 20, and 40 mg pantoprazole in children (5-11 years) with symptomatic gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr. 2006;42:384–391
  17. Dean BB, Gano AD, Knight K, Ofman JJ, Fass R. Proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol. 2004;2:656–664
  18. Moore DJ, Tao BS, Lines DR, Hirte C, Heddle ML, Davidson GP. Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux. J Pediatr. 2003;143:219–223
  19. Omari TI, Davidson GP, Bondarov P, Naucler E, Nilsson , Lundborg P. Pharmacokinetics and acid-suppressive effects of esomeprazole in infants 1-24 months old with symptoms of gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr. 2007;45:530–537
  20. Omari TI, Haslam RR, Lundborg P, Davidson GP. Effect of omeprazole on acid gastroesophageal reflux and gastric acidity in preterm infants with pathological acid reflux. J Pediatr Gastroenterol Nutr. 2007;44:41–44
  21. Orenstein SR, Shalaby TM, Kelsey SF, Frankel E. Natural history of infant reflux esophagitis: symptoms and morphometric histology during one year without pharmacotherapy. Am J Gastroenterol. 2006;101:628–640
  22. Fiedorek S, Tolia V, Gold BD, Huang B, Stolle J, Lee C, et al. Efficacy and safety of lansoprazole in adolescents with symptomatic erosive and non-erosive gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr. 2005;40:319–327
  23. Orlando RC. Mechanisms of reflux-induced epithelial injuries in the esophagus. Am J Med. 2000;108(Suppl 4a):104S–108S
  24. Condino AA, Sondheimer J, Pan Z, Gralla J, Perry D, O'Connor JA. Evaluation of infantile acid and nonacid gastroesophageal reflux using combined pH monitoring and impedance measurement. J Pediatr Gastroenterol Nutr. 2006;42:16–21
  25. Orenstein SR. Infantile reflux: different from adult reflux. Am J Med. 1997;103:114S–119S
  26. Feranchak AP, Orenstein SR, Cohn JF. Behaviors associated with onset of gastroesophageal reflux episodes in infants: prospective study using split-screen video and pH probe. Clin Pediatr. 1994;33:654–662
  27. Gunasekaran TS, Hassall EG. Efficacy and safety of omeprazole for severe gastroesophageal reflux in children. J Pediatr. 1993;123:148–154
  28. Hassall E, Kerr W, El-Serag HB. Characteristics of children receiving proton pump inhibitors continuously for up to 11 years duration. J Pediatr. 2007;150:262–267
  29. Vandenplas Y, Hassall E. Mechanisms of gastroesophageal reflux and gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr. 2002;35:119–136
  30. Hassall E. Co-morbidities in childhood Barrett's esophagus. J Pediatr Gastroenterol Nutr. 1997;25:255–260
  31. Canani RB, Cirillo P, Roggero P, Romano C, Malamisura B, Terrin G, et al. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics. 2006;117:e817–e820
  32. Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA. 2004;292:1955–1960

 Takeda Global Research & Development Center, Inc sponsored the clinical trial (ClinicalTrials.gov NCT00324974) and data analysis (TAP Pharmaceutical Products, Inc is now part of Takeda Global Research & Development Center, Inc.). The sponsor provided no financial support for the preparation of this article. S.O., E.H., and W.F.-J. have served as consultants to Takeda Global Research & Development Center, Inc, as well as to other companies making drugs in the same class. S.A. and M.R. are employed by Takeda Global Research & Development Center, Inc.

 No reprints are available from the authors.

PII: S0022-3476(08)00864-0

doi: 10.1016/j.jpeds.2008.09.054

The Journal of Pediatrics
Volume 154, Issue 4 , Pages 514-520.e4 , April 2009

Article Tools

* Image Usage & Resolution